Retinitis Pigmentosa: Market Size, Trend, by Treatment Type (Gene Therapy, Stem Cell Therapy), by Disease Type (Autosomal Dominant, Autosomal Recessive, X-Linked, Congenital), by Patient Demographic, End Users, Region, Major Players – Global Forecast to 2030
Wissen Research analyses that the global retinitis pigmentosa market is estimated at USD 10 billion in 2023 and is projected to reach USD 15.5 billion by 2030, expected to grow at a CAGR of 6.5% during the forecast period, 2024-2030.
Key driving factors of Retinitis Pigmentosa market include rising prevalence, growing investment in advanced research and innovative treatment methodologies and emerging markets with increasing healthcare spending and awareness.
Challenges in the multiple sclerosis domain include limited treatment options and healthcare infrastructure disparities.
Pharmacological Therapies (supplements and anti-oxidants) have held the largest share in the market since 2022, with North America dominating the regional market share.
Key players functioning in retinitis pigmentosa sector are Spark Therapeutics, Inc., Proqr Therapeutics N.V., Gensight Biologics, Biogen Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, among others
Further, the US with USD 4 billion market in 2024, holds majority share in the global retinitis pigmentosa market and is likely to remain the leading region growing a CAGR of 6.5% within this market, during the forecast period.
Drivers: Rising prevalence of Retinitis Pigmentosa globally
Retinitis pigmentosa (RP) has a global prevalence estimated at 1 in 3,000 to 1 in 5,000 individuals, affecting more than 1.5 million people worldwide, according to National Institutes of Health (NIH). The rising prevalence is driving market growth by increasing the demand for effective treatments and diagnostic tools. As genetic testing becomes more accessible, more cases are being identified, prompting investment in research and development for innovative therapies like gene therapy and retinal implants. Additionally, heightened awareness and the economic burden of vision loss associated with RP are pushing healthcare systems to prioritize solutions, further expanding the market.
Opportunities: Rising demand for CRISPR-based gene editing and personalized medicine with premium pricing strategies in Retinitis Pigmentosa Market
The rising demand for CRISPR-based gene editing and personalized medicine in the Retinitis Pigmentosa (RP) market is driven by its ability to precisely target genetic mutations causing RP, enabling tailored therapies with premium pricing potential. For instance, Intellia Therapeutics partnered with SparingVision to develop CRISPR-based ocular therapies, while the Foundation Fighting Blindness has invested $6.5 million in research for inherited retinal diseases, including CRISPR applications. Such collaborations and funding efforts highlight the growing interest in leveraging cutting-edge technologies to revolutionize RP treatment and improve patient outcomes.
Challenges: Healthcare Infrastructure Disparities in Retinitis Pigmentosa Market
Healthcare infrastructure disparities significantly challenge the Retinitis Pigmentosa (RP) market by limiting access to essential diagnostic and treatment services. In many regions, especially in low-income countries, inadequate healthcare facilities and a shortage of trained professionals hinder timely diagnosis and effective management of RP. For example, in rural India, the prevalence of RP is notably high due to factors like consanguineous marriages, yet access to specialized care and genetic counseling remains limited. This disparity not only affects patient outcomes but also exacerbates the social and economic burden on families, as they struggle with the implications of vision loss. Moreover, the financial strain on healthcare systems from untreated RP cases highlights the urgent need for investment in healthcare infrastructure to ensure equitable access to innovative therapies and support services for all patients.
The retinitis pigmentosa market report offers information on the latest advancements in the industry, as well as product portfolio analysis, supply chain/value chain analysis, market share, and the effects of localized and domestic players. It also analyses potential revenue opportunities and changes in market regulations, as well as market size, category market growth, application dominance, product approvals, product launches, geographic expansions, and technological innovations. For an analyst brief and other information on the retinitis pigmentosa market, get in touch with Wissen Research. Our staff can assist you in making well-informed decisions that will lead to market expansion.
Pharmacological Therapies Segment Dominated the Retinitis Pigmentosa Market by Treatment Type in 2023
The pharmacological therapies segment dominated the Retinitis Pigmentosa (RP) market by treatment type in 2023 due to a combination of factors, including the limited availability of approved treatments, with LUXTURNA being the only gene therapy specifically for patients with RPE65 mutations. As most RP patients rely on best supportive care, such as vitamin supplements and visual aids, pharmacological interventions formed a significant portion of the market. Additionally, ongoing research and advancements in the clinical pipeline, including novel therapies targeting specific genetic mutations like Ultevursen for the USH2A gene, have bolstered this segment.
Autosomal Recessive RP held the largest market share in 2023, accounting for a significant 65% market share.
Autosomal recessive Retinitis Pigmentosa (RP) held the largest market share in 2023, accounting for 65%, due to its higher prevalence compared to other inheritance patterns and the significant advancements in identifying causative genetic mutations. Mutations in genes like USH2A, responsible for 10–15% of autosomal recessive RP cases, have driven research and development of targeted therapies. Additionally, the autosomal recessive inheritance pattern, which requires two copies of a mutated gene from both parents, is more common in populations with consanguineous marriages, further contributing to its dominance. This segment’s growth is also supported by increasing genetic testing capabilities, enabling better diagnosis and therapeutic interventions for affected individuals.
North America held the largest market share in Retinitis Pigmentosa Market in the forecast period
Retinitis Pigmentosa market analysis encompassed a detailed evaluation of five key regions: North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America. These regions were assessed based on healthcare infrastructure, regulatory frameworks, technological advancements, and market trends. North America held the largest market share in the Retinitis Pigmentosa (RP) market during the forecast period, primarily due to its well-established healthcare infrastructure, high levels of awareness about retinal diseases, and significant investment in research and development. In 2022, this region accounted for a substantial portion of the market, driven by the presence of major pharmaceutical companies and advanced diagnostic technologies. The United States, in particular, has a high prevalence of retinal disorders, which has led to increased demand for effective treatments and diagnostic services. Additionally, favorable reimbursement policies and a growing focus on innovative treatment methods further bolster the market’s growth in North America, positioning it as a leader in the global RP landscape.
Major players operating in Retinitis Pigmentosa market are:
BRAND ANALYSIS: RETINITIS PIGMENTOSA MARKET
Sources: Secondary ResearchPRIMARY INSIGHTS FROM KEY OPINION LEADERS
Particulars | Details |
Report | Retinitis Pigmentosa Market |
Forecast Period | 2024-2030 |
Base Year | 2023 |
Format | |
Estimated Market Size (2023) | USD 10 Billion |
CAGR (2024-2030) | 6.5% |
Number of Pages | 170 |
Number of Tables | 161 |
Number of Figures | 33 |
Key Segments | Retinitis Pigmentosa Market Treatment Outlook (Gene Therapy, Cell Therapy, Pharmacological Treatment, Innovative Therapeutics, Implantable Devices)
Retinitis Pigmentosa Market Disease Outlook (Autosomal Dominant Retinitis Pigmentosa, Autosomal Recessive Retinitis Pigmentosa, X-Linked Retinitis Pigmentosa, Congenital Retinitis Pigmentosa) Retinitis Pigmentosa Market Patient Demographic Outlook (Retinitis Pigmentosa Treatment Market by, Age Group, Retinitis Pigmentosa Treatment Market by, Gender) Retinitis Pigmentosa Market End User Outlook (Hospitals and Clinics, Specialized Eye Care Centers, Home Care and Ambulatory Care Centers, Research Institutes and Biotechnology Companies) |
Regions Covered | North America: US and Canada Europe: Germany, UK, France, Italy, Spain, and Rest of the Europe Asia-Pacific: China, Japan, India, South Korea, Australia and New Zealand, and Rest of the Asia-Pacific Latin America Middle East and Africa |
Key Players Covered (Majority Share Holders) | Spark Therapeutics, Inc. (US), Proqr Therapeutics N.V. (Netherlands), Gensight Biologics (France), Biogen Inc. (US) , Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Orphalan SA (France), Aveo Pharmaceuticals, Inc. (US) , Vanda Pharmaceuticals Inc. (US), Oxurion NV (Belgium), Alkeus Pharmaceuticals, Inc. (US) |
Introduction
MARKET DEFINITION
The Retinitis Pigmentosa (RP) Treatment Market refers to the global market for medical products and therapies designed to treat Retinitis Pigmentosa, a group of rare genetic disorders that cause progressive degeneration of the retina, leading to vision impairment and, in some cases, blindness.
FIGURE: RETINITIS PIGMENTOSA MARKET SEGMENTS
Sources: Company Websites and Wissen Research Analysis
FIGURE: YEARS FRAMEWORK CONSIDERED IN THE STUDY
Sources: Wissen Research Analysis
Key Stakeholders
Key objectives of the Study
Research Methodology
The aim of the study is to examine the key market forces such as drivers, opportunities, restraints, challenges, and strategies impacting the market ecosystem. To monitor company advancements such as patents granted, product launches, expansions, and collaborations of key players, analysing their competitive landscape based on various parameters of business and product strategy. Markey sizing will be estimated using top-down and bottom-up approaches. Using market breakdown and data triangulation techniques, market sizing of segments and sub-segments will be estimated.
FIGURE: RESEARCH DESIGN
Sources: Wissen Research Analysis
Research Approach
Collecting Secondary Data
The process of collating secondary research data involves the utilization of databases, secondary sources, annual reports, investor presentations, directories, and SEC filings of companies. Secondary research will be utilized to identify and gather information beneficial for the in-depth, technical, market-oriented, and commercial analysis of the retinitis pigmentosa treatment market. A database of the key industry leaders will also be compiled using secondary research.
Collecting Primary Data
The primary research data will be conducted after acquiring knowledge about the retinitis pigmentosa treatment market scenario through secondary research. A significant number of primary interviews will be conducted with stakeholders from both the demand and supply side (including various industry experts, such as Vice Presidents (VPs), Chief X Officers (CXOs), Directors from business development, marketing and product development teams, product manufacturers) across major countries within Europe, Asia Pacific, North America, Latin America, and Middle East. Primary data for this report will be collected through questionnaires, emails, and telephonic interviews.
FIGURE: BREAKDOWN OF PRIMARY INTERVIEWS FROM SUPPLY SIDE
FIGURE: BREAKDOWN OF PRIMARY INTERVIEWS FROM DEMAND SIDE
FIGURE: PROPOSED PRIMARY PARTICIPANTS FROM DEMAND AND SUPPLY SIDE
Note: Above mentioned companies are non- exhaustive
Market Size Estimation
All major manufacturers offering various multiple sclerosis will be identified at the global/regional level. Revenue mapping will be done for the major players, which will further be extrapolated to arrive at the global market value of each type of segment. The market value of multiple sclerosis market will also split into various segments and sub segments at the region level based on:
FIGURE: REVENUE MAPPING BY COMPANY (ILLUSTRATION)
Sources: Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentation, Paid Database, and Wissen Research Analysis.
FIGURE: REVENUE SHARE ANALYSIS OF KEY PLAYERS (SUPPLY SIDE)
Sources: Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentation, Paid Database, and Wissen Research Analysis.
FIGURE: MARKET SIZE ESTIMATION TOP-DOWN AND BOTTOM-UP APPROACH
Sources: Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentation, Paid Database, and Wissen Research Analysis.
FIGURE: ANALYSIS OF DROCS FOR GROWTH FORECAST
Sources: The American Academy of Ophthalmology (AAO), National Eye Institute (NEI), European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), ScienceDirect, ClinicalTrials.gov, Investigative Ophthalmology & Visual Science (IOVS), Ophthalmology Journal, PubMed, Company Presentation, Annual Reports/SEC Filings, Press Releases of Key Players, News Articles/Journals, Primary Market Research, and Paid Databases Among Others
FIGURE: GROWTH FORECAST ANALYSIS UTILIZING MULTIPLE PARAMETERS
Sources: Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentation, Paid Database, and Wissen Research Analysis.
Research Design
After arriving at the overall market size-using the market size estimation processes-the market will be split into several segments and sub segment. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub segment, the data triangulation, and market breakdown procedures will be employed, wherever applicable. The data will be triangulated by studying various factors and trends from both the demand and supply sides in the multiple sclerosis market industry.
Sources: The American Academy of Ophthalmology (AAO), National Eye Institute (NEI), European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), ScienceDirect, ClinicalTrials.gov, Investigative Ophthalmology & Visual Science (IOVS), Ophthalmology Journal, PubMed, Company Presentation, Annual Reports/SEC Filings, Press Releases of Key Players, News Articles/Journals, Primary Market Research, and Paid Databases Among Others
1.1 KEY OBJECTIVES
1.2 DEFINITIONS
1.2.1 IN SCOPE
1.2.2 OUT OF SCOPE
1.3 SCOPE OF THE REPORT
1.4 SCOPE RELATED LIMITATIONS
1.5 KEY STAKEHOLDERS
2. RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.2 RESEARCH METHODOLOGY / DESIGN
2.3 MARKET SIZE ESTIMATION APPROACHES
2.3.1 SECONDARY RESEARCH
2.3.2 PRIMARY RESEARCH
2.3.2.1 KEY INSIGHTS FROM INDUSTRY EXPERTS
2.4 DATA VALIDATION & TRIANGULATION
2.5 ASSUMPTIONS OF THE STUDY
3. EXECUTIVE SUMMARY & PREMIUM CONTENT
3.1 GLOBAL MARKET OUTLOOK
3.2 KEY MARKET FINDINGS
4. MARKET OVERVIEW
4.1 RETINITIS PIGMENTOSA: DISEASE OVERVIEW
4.1.1 INTRODUCTION
4.1.2 SIGNS AND SYMPTOMS
4.1.3 CAUSES OF RETINITIS PIGMENTOSA
4.1.4 CLASSIFICATION OF RETINITIS PIGMENTOSA
4.1.5 PATHOPHYSIOLOGY
4.1.6 DIAGNOSIS OF RETINITIS PIGMENTOSA
4.1.6.1 DIAGNOSTIC TESTS
4.1.6.2. DIFFERENTIAL DIAGNOSIS OF RETINITIS PIGMENTOSA
4.1.6.3 DIAGNOSTIC GUIDELINES
4.1.7 PROGNOSIS
4.1.8 TREATMENT OF RETINITIS PIGMENTOSA
4.1.8.1 FUTURE TREATMENT MODALITIES
4.1.8.2 GENERAL RECOMMENDATIONS FOR RETINITIS PIGMENTOSA TREATMENT
4.1.8.3 TREATMENT GUIDELINES FOR RETINITIS PIGMENTOSA
4.2 MARKET DYNAMICS
4.2.1 MARKET DRIVERS
4.2.2MARKET OPPORTUNITIES
4.2.3 RESTRAINTS/CHALLENGES
4.3 END USER PERCEPTION
4.4 NEED GAP ANALYSIS
4.5 KEY CONFERENCES
4.6 EPIDEMIOLOGY
4.7 PATIENT JOURNEY MAPPING: RETINITIS PIGMENTOSA
4.8 SUPPLY CHAIN / VALUE CHAIN ANALYSIS
4.9 INDUSTRY TRENDS
4.10 PORTER’S FIVE FORCES ANALYSIS
4.11 REGULATORY LANDSCAPE
4.11.1 NORTH AMERICA
4.11.2 EUROPE
4.11.3 ASIA PACIFIC
4.12 REIMBURSEMENT SCENARIO
5. PATENT ANALYSIS
5.1 TOP ASSIGNEES
5.2 GEOGRAPHY FOCUS OF TOP ASSIGNEES
5.3 LEGAL STATUS
5.4 TECHNOLOGY EVOLUTION
5.5 KEY PATENTS
5.6 PATENT TRENDS AND INNOVATIONS
6. LINICAL TRIAL ANALYSIS
6.1 ANALYSIS BY TRIAL REGISTRATION YEAR
6.2 ANALYSIS BY PHASE OF DEVELOPMENT
6.3 ANALYSIS BY TRIAL STATUS
6.4 ANALYSIS BY NUMBER OF PATIENTS ENROLLED
6.5 ANALYSIS BY STUDY DESIGN
6.6 ANALYSIS BY TYPE OF THERAPY / DRUG
6.7 ANALYSIS BY GEOGRAPHY
6.8 ANALYSIS BY KEY SPONSORS / COLLABORATORS
7. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET BY, TREATMENT TYPE (2023-2030, USD MILLION)
7.1 GENE THERAPY
7.1.1 GENE EDITING
7.1.2 GENE REPLACEMENT THERAPY
7.2 STEM CELL THERAPY
7.2.1 RETINA REGENERATION
7.2.2 STEM CELL LINES
7.3 PHARMACOLOGICAL TREATMENT
7.3.1 RETINOID-BASED DRUGS
7.3.2 ANTIOXIDANTS AND SUPPLEMENTS
7.4 INNOVATIVE THERAPEUTICS
7.5 IMPLANTABLE DEVICES
7.5.1 RETINAL IMPLANTS
7.5.2 RETINAL PROSTHESES
8. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET BY, DISEASE TYPE / MUTATION (2023-2030, USD MILLION)
8.1 AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA
8.2 AUTOSOMAL RECESSIVE RETINITIS PIGMENTOSA
8.3 X-LINKED RETINITIS PIGMENTOSA
8.4 CONGENITAL RETINITIS PIGMENTOSA
9. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET BY, PATIENT DEMOGRAPHICS (2023-2030, USD MILLION)
9.1 RETINITIS PIGMENTOSA TREATMENT MARKET BY, AGE GROUP
9.1.1 PEDIATRIC PATIENTS
9.1.2 ADULTS
9.1.3 ELDERLY PATIENTS
9.2 RETINITIS PIGMENTOSA TREATMENT MARKET BY, GENDER
9.2.1 MALE PATIENTS
9.2.2 FEMALE PATIENTS
10. GLOBAL RETINITIS PIGMENTOSA TREATMENT MARKET BY, END-USER (2023-2030, USD MILLION)
10.1 HOSPITALS AND CLINICS
10.2 SPECIALIZED EYE CARE CENTERS
10.3 HOME CARE AND AMBULATORY CARE CENTERS
10.4 RESEARCH INSTITUTES AND BIOTECHNOLOGY COMPANIES
11. GLOBAL PHARMACEUTICAL CDMO MARKET BY, REGION (2023-2030, USD MILLION)
11.1 NORTH AMERICA
11.1.1 US
11.1.2 CANADA
11.2 EUROPE
11.2.1 GERMANY
11.2.2. FRANCE
11.2.3 SPAIN
11.2.4 ITALY
11.2.5 UK
11.2.6 REST OF THE EUROPE
11.3 ASIA-PACIFIC
11.3.1 CHINA
11.3.2 JAPAN
11.3.3 INDIA
11.3.4 AUSTRALIA AND NEW ZEALAND
11.3.5 SOUTH KOREA
11.3.6 REST OF THE ASIA-PACIFIC
11.4 MIDDLE EAST AND AFRICA
11.5 LATIN AMERICA
12. COMPETITIVE ANALYSIS
12.1 PRODUCT PIPELINE: RETINITIS PIGMENTOSA TREATMENT
12.2 KEY PLAYERS FOOTPRINT ANALYSIS
12.3 MARKET SHARE ANALYSIS (2023/2024)
12.4 REGIONAL SNAPSHOT OF KEY PLAYERS
12.5 R&D EXPENDITURE OF KEY PLAYERS
13. COMPANY PROFILES
13.1 SPARK THERAPEUTICS, INC. (SUBSIDIARY OF ROCHE)
13.1.1 BUSINESS OVERVIEW
13.1.2 PRODUCT PORTFOLIO
13.1.3 FINANCIAL SNAPSHOT
13.1.4 RECENT DEVELOPMENTS
13.1.4.1 MERGER/ACQUISITIONS
13.1.4.2 PRODUCT APPROVAL/LAUNCHES
13.1.4.3 PARTNERSHIP/COLLABORATIONS/AGREEMENTS
13.1.4.4 EXPANSIONS
13.2 PROQR THERAPEUTICS N.V. (NETHERLANDS)
13.3 GENSIGHT BIOLOGICS (FRANCE)
13.4 BIOGEN INC. (US)
13.5 REGENERON PHARMACEUTICALS, INC. (US)
13.6 NOVARTIS AG (SWITZERLAND)
13.7 ORPHALAN SA (FRANCE)
13.8 AVEO PHARMACEUTICALS, INC. (US)
13.9 VANDA PHARMACEUTICALS INC. (US)
13.10 HORAMA (FRANCE)
13.11 OXURION NV (BELGIUM)
13.12 ALKEUS PHARMACEUTICALS, INC. (US)
13.13 MEIRAGTX (UK)
13.14 ACUCELA INC. (US)
13.15 NOTAL VISION LTD. (ISRAEL)
13.16 LUMEA INC. (US)
13.17 EYEGATE PHARMACEUTICALS, INC. (US)
13.18 SENJU PHARMACEUTICAL CO., LTD. (JAPAN)
13.19 4D MOLECULAR THERAPEUTICS, INC. (US)
13.20 ASTELLAS PHARMA INC. (JAPAN)
13.21 CLINO CORPORATION (JAAN)
14. APPENDIX
14.1 INDUSTRY SPEAK
14.2 QUESTIONNAIRE/DISCUSSION GUIDE
14.3 AVAILABLE CUSTOM WORK
14.4 ADJACENT STUDIES
14.5 AUTHORS
REFERENCES
Key Notes:
Note 1 – Contents in the ToC / market segments are tentative and might change as the research proceeds.
Note 2 – List of companies is not exhaustive and might change during the course of study.
Note 3 – Details on key financials might not be captured in case of unlisted companies.
Note 4 – SWOT analysis will be provided for top 3-5 companies.
The global market for retinitis pigmentosa was valued at approximately USD 10 billion in 2023, and is projected to increase to USD 11.3 billion in 2025.
The global retinitis pigmentosa market is anticipated to grow at an annual growth rate of 6.5% from 2024 to 2030 to reach USD 15.7 billion, by 2030.
The major end-users in the retinitis pigmentosa market include Hospitals and Clinics, Specialized Eye Care Centers, Home Care and Ambulatory Care Centers, Research Institutes and Biotechnology Companies, with hospitals still being a significant segment due advanced infrastructure, higher patient intake, and ability to invest in cutting-edge technologies for comprehensive diagnosis and treatment, holding nearly 40% of the market share.
Leading players within the retinitis pigmentosa market are Spark Therapeutics, Inc. (US), Proqr Therapeutics N.V. (Netherlands), Biogen Inc. (US) , Regeneron Pharmaceuticals, Inc. (US), Novartis AG (Switzerland)
The market is mildly consolidated at top, comprising 10 key players with them holding almost 50% of the market, while it remains lightly fragmented at the lower levels, with numerous small and mid-sized companies operating at regional and national level.
